Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval

Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues

Regenxbio plans to resubmit its Hunter syndrome gene therapy RGX-121 after the FDA reversed course, saying existing data are sufficient for accelerated approval review.